此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Biomarkers as Prognostic Factors of Silent, Cerebral Infarctions in Patients Undergoing High-thromboembolic-risk Transcatheter Interventions (PRINCESS)

2026年9月24日 更新者:Stergios Tzikas、Aristotle University Of Thessaloniki

Background: The transcatheter interventions with high thromboembolic risk, as transcatheter carotid angioplasty or transcatheter ablation of cardiac arrhythmias are associated with asymptomatic strokes- silent strokes. The silent strokes are cerebral infarctions with small diameter which are diagnosed with computed tomography or magnetic resonance imaging (MRI). Silent cerebral infarctions (SCIs) are associated with neurological deficits, cognitive impairment, high mortality and high risk of dementia. There are biomarkers, as neuron specific enolase (NSE) and neurofilaments (NFLs) which are indicated for the prognosis of these patients.

Aim: The aim of this study is the prognostic role of biomarkers NSE and NFLs in patients undergoing high-thromboembolic-risk transcatheter interventions. This study will assess the hypothesis that the level of these biomarkers could predict the development of SCIs and the long-term cognitive impairment.

Study type - materials: This study is a prospective, observational study. Patients undergoing highthromboembolic-risk transcatheter interventions will be included in this study.

Protocol: All the demographic and clinical characteristics of patients will be recorded. Blood samples will be obtained, 24 hours pre-interventionally and 24 hours post-interventionally. The blood samples will be centrifugated and will be freezed at -80 οC for the measurement of biomarkers. MRI will be conducted 24 hours pre- and postinterventionally. The neurological assessment will be conducted with the use of Mini Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) questionnaires, 24 hours pre-interventionally, 24 hours and 6 months postinterventionally.

Outcomes: The primary outcome is the association between level of biomarkers and the development of SCIs in MRI post-procedurally. Secondary outcomes concern the probable association of biomarkers with the cognitive impairment. The data will be assessed with statistical analysis and will be interpreted. The results of this study will be published with the view to create algorithms and prognostic tools for appropriate management of these patients.

研究概览

研究类型

观察性的

注册 (估计的)

100

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Stergios Tzikas, Associate Professor of Cardiology
  • 电话号码:002313312344
  • 邮箱:tzikas@auth.gr

研究联系人备份

  • 姓名:Alexandros Evangeliou, Resident fo Cardiology
  • 电话号码:00306977598469
  • 邮箱:apevange@auth.gr

学习地点

      • Thessaloniki、希腊、54642
        • 招聘中
        • Third Department of Cardiology, Aristotle University of Thessaloniki, Greece
        • 接触:
          • Stergios Tzikas, Associate Professor of Cardiology
          • 电话号码:002313312344
          • 邮箱:tzikas@auth.gr
        • 接触:
          • Alexandros Evangeliou, Resident of Cardiology
          • 电话号码:00306977598469
          • 邮箱:apevange@auth.gr
        • 副研究员:
          • Vassilios Vassilikos
        • 首席研究员:
          • Stergios Tzikas
        • 副研究员:
          • Alexandros Evangeliou
        • 副研究员:
          • Christos Karkos

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients undergoing high-thromboembolic-risk transcatheter interventions (Carotid scenting and cardiac ablation procedure for cardiac arrhythmias.

描述

Inclusion Criteria:

  1. Age > 18 years
  2. Signed consent
  3. Agreement on monitoring required by the study

Exclusion Criteria:

  1. Age < 18 years
  2. Patients with known malignancies
  3. Patients who are unable or unwilling to give consent

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:CASE_CONTROL
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Patients with new silent strokes at post-procedural MRI

Patients diagnosed with carotid artery disease who will undergo transcatheter revascularization surgery and patients with cardiac arrhythmias who will undergo transcatheter ablation procedure will be enrolled.

Patients without new silent strokes at post-procedural MRI

Patients diagnosed with carotid artery disease who will undergo transcatheter revascularization surgery and patients with cardiac arrhythmias who will undergo transcatheter ablation procedure will be enrolled.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Difference in serum neuron-specific enolase concentration between participants with and without new silent cerebral infarcts
大体时间:Blood sampling and brain MRI at 24 hours before and 24 hours after the procedure; comparison based on the 24-hour post-procedural NSE concentration.

In participants undergoing carotid artery stenting, serum neuron-specific enolase (NSE) concentration at 24 hours after the procedure will be compared between participants with and without new silent cerebral infarcts. NSE will be measured using an enzyme-linked immunosorbent assay (ELISA). Concentrations and the between-group difference will be expressed in ng/mL.

Blood sampling and brain MRI at 24 hours before and 24 hours after the procedure; comparison based on the 24-hour post-procedural NSE concentration.
Difference in serum neurofilament light chain concentration between participants with and without new silent cerebral infarcts
大体时间:Blood sampling and brain MRI at 24 hours before and 24 hours after the procedure; comparison based on the 24-hour post-procedural NfL concentration

In participants undergoing carotid artery stenting, serum neurofilament light chain (NfL) concentration at 24 hours after the procedure will be compared between participants with and without new silent cerebral infarcts. NfL will be measured using a dot blot assay. Concentrations and the between-group difference will be expressed in μg/mL.

New silent cerebral infarcts are defined as new ischemic lesions on post-procedural diffusion-weighted brain MRI that were absent on baseline MRI, without corresponding new clinical neurological symptoms.

Blood sampling and brain MRI at 24 hours before and 24 hours after the procedure; comparison based on the 24-hour post-procedural NfL concentration

次要结果测量

结果测量
措施说明
大体时间
Correlation between serum neuron-specific enolase concentration and change in Montreal Cognitive Assessment score
大体时间:24 hours before and 24 hours after the procedure.

The correlation between serum neuron-specific enolase (NSE) concentration at 24 hours after the procedure and the change in Montreal Cognitive Assessment (MoCA) total score will be assessed using Spearman's rank correlation coefficient.

NSE will be measured using an enzyme-linked immunosorbent assay (ELISA) and expressed in ng/mL.

MoCA total scores range from 0 to 30 points, with higher scores indicating better cognitive performance. Change will be calculated as the 24-hour post-procedural score minus the pre-procedural score; negative values indicate deterioration

24 hours before and 24 hours after the procedure.
Correlation between serum neurofilament light chain concentration and change in Montreal Cognitive Assessment score
大体时间:24 hours before and 24 hours after the procedure.

The correlation between serum neurofilament light chain (NfL) concentration at 24 hours after the procedure and the change in Montreal Cognitive Assessment (MoCA) total score will be assessed using Spearman's rank correlation coefficient.

NfL will be measured using a dot blot assay and expressed in μg/mL.

MoCA total scores range from 0 to 30 points, with higher scores indicating better cognitive performance. Change will be calculated as the 24-hour post-procedural score minus the pre-procedural score; negative values indicate deterioration.

24 hours before and 24 hours after the procedure.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年6月10日

初级完成 (估计的)

2027年5月1日

研究完成 (估计的)

2027年7月1日

研究注册日期

首次提交

2025年12月5日

首先提交符合 QC 标准的

2026年9月24日

首次发布 (实际的)

2026年9月28日

研究记录更新

最后更新发布 (实际的)

2026年9月28日

上次提交的符合 QC 标准的更新

2026年9月24日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • 5141

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅